Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

5-azacytidine resistance: THP-1 control vs. THP-1 resistant cell line(TAR) by CodeLinkTM Human Whole Genome Bioarray.

ABSTRACT: Generated AZA resistant cell line (TAR) and analysis markedly different gene expression levels between THP-1 and TAR.

ORGANISM(S): Homo sapiens

PROVIDER: GSE37630 | GEO | 2012/04/28

SECONDARY ACCESSION(S): PRJNA162439

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

5-azacytidine resistance: THP-1 control vs. THP-1 resistant cell line(TAR) by CodeLinkTM Human Whole Genome Bioarray.

Project description:Generated AZA resistant cell line (TAR) and analysis markedly different gene expression levels between THP-1 and TAR. Two condition experiment, THP-1 control vs. AZA resistant cell line.

2012-04-27 | E-GEOD-37630 | biostudies-arrayexpress

LC-MSMS of the MHC-I immunopeptidome of AML cell line, THP-1

Project description:The hypomethylating agent 5-azacytidine (AZA) is the first-line induction therapy for AML patients unsuitable for intensive chemotherapy. The anti-tumor effect of AZA results in part from T-cell cytotoxic responses against MHC-I-associated peptides (MAPs) deriving from hypermethylated genomic regions such as cancer-testis antigens (CTAs), or endogenous retroelements (EREs). However, clear evidence supporting higher ERE MAPs presentation after AZA treatment in AML is lacking. Interestingly, we find that AZA-mediated DNMT2 inhibition leads to autophagy induction, which is responsible for mitigating ERE MAPs generation. To validate our findings, we examined the immunopeptidome of THP-1 cells treated with AZA combined with autophagy inhibitor, Spautin-1 or decitabine (DAC, non-DNMT2 inhibiting HMA) through a proteogenomic approach.

2024-04-17 | PXD046853 | Pride

Bortezomib resistance in THP-1 cell line

Project description:Bortezomib is a proteasome inhibitor used in severel different hematological malignancies. Resistance to this drug is still poorly understood. In order get more insight in the resistance mechanism, we developed several bortezomib resistant subclones of the THP-1 monocytic/macrophage cell line. On these subclones expression arrays were performed. We performed expression array three different bortezomib resistant subclones of the THP-1 cell line. The resistant subclones were spotted against the parental THP-1 wildtype cell line.

2008-06-14 | E-GEOD-11771 | biostudies-arrayexpress

Bortezomib resistance in THP-1 cell line

2008-06-14 | GSE11771 | GEO

Array CGH in TAR syndrome

Project description:The series represents the analysis data of four TAR syndrome patients by submegabase resolution BAC array. Keywords: array CGH

2007-01-07 | GSE5781 | GEO

Bortezomib resistance in THP-1 cell line

| S-ECPF-GEOD-11771 | biostudies-other

tar pit metagenome

Project description:Microbial community succession during animal decomposition in a tar seep.

| PRJNA340972 | ENA

RNA Sequencing of Novel HIV RNA TAR-gag and Host Genome of EVs from HIV-1 Infected Cells

Project description:We performed a 3' RACE of a novel HIV RNA TAR-gag in order to determine the sequence of the RNA at the 3' end. Our data had shown that TAR-gag was potentially a noncoding RNA and our hypothesis was that TAR-gag ended somewhere prior to the end of the gag region of the HIV genome. The 3' RACE experiment showed that TAR-gag actually consists of four different RNA clusters, the longest of which ends at 615 bases from the transcription start site; this is in the middle of the p17 region of the gag gene. In addition, we sequenced all host RNAs in the EVs.

2017-08-09 | GSE102364 | GEO

Brevundimonas abyssalis TAR-001

Project description:Whole genome sequencing of Brevundimonas abyssalis TAR-001

| PRJDB1125 | ENA

RNA-seq of human MDS/AML cell line OCI-M2 treated with 5-azacytidine and sulforaphane

Project description:The RNA sequencing experiment is part of the study: “Modulating Redox Balance Restores Azacytidine Efficacy in Hypomethylating Agent Resistant Disease.” In the study we generated myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) OCI-M2 cell line that is resistant to hypomethylating therapy by 5-azacytidine (AZA). By modulation of the redox environment via modification of redox sensor KEAP1 using sulforaphane (SFN) in these cells we were able to restore sensitivity to AZA. We used RNA sequencing to define transcriptomic differences between AZA sensitive (AZA-S) and AZA resistant (AZA-R) cells and to characterize how the transcriptome is changing upon treatment of these cells with AZA, SFN and combination of both.

2021-07-16 | E-MTAB-10635 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data